BioCentury
ARTICLE | Company News

San Raffaele, MolMed deal

May 18, 2015 7:00 AM UTC

MolMed exercised an option to purchase a chimeric antigen receptor (CAR)- splice variant v6 of CD44 (CD44v6) from San Raffaele. MolMed said the compound has applications in hematological and solid tumors. The companies could not be reached for details. MolMed, which was formed as a JV between Boehringer Mannheim GmbH and San Raffaele in 1996, has rights under a 2001 deal with the hospital to IP generated under research in gene and molecular therapy to treat cancer and AIDS (see BioCentury, Nov. 25, 1996). ...